Multimodal Mechanism of Antitumoral Ni(II) Thiosemicarbazones: Deep Mechanistic Understanding of ROS Dynamics,

Lorenzo Verderi1, Silvana Pinelli2, Gloria Cenci1,3

  • 1Department of Chemistry, Life Sciences and Environmental Sustainability, University of Parma, Parco Area delle Scienze 17/a, Parma 43124, Italy.

ACS Omega
|June 15, 2026
PubMed

Insights

This study introduces Ni-(II) thiosemicarbazone complexes as novel anticancer agents. The Ni4 complex shows high selectivity and induces cancer cell death through DNA interaction and reactive oxygen species (ROS) modulation, with albumin aiding targeted delivery.

Area of Science:

  • Inorganic Chemistry
  • Medicinal Chemistry
  • Cancer Biology

Background:

  • Cancer remains a leading cause of death globally, with drug resistance necessitating novel therapeutic strategies.
  • Thiosemicarbazones are a class of compounds known for their multimodal antitumoral activity.
  • Nickel(II) complexes offer unique redox properties and coordination chemistry relevant to drug development.

Purpose of the Study:

  • To synthesize and evaluate novel Nickel(II) thiosemicarbazone complexes for anticancer activity.
  • To elucidate the mechanisms of action, including apoptosis induction and selectivity.
  • To investigate the role of albumin in the targeted delivery of these complexes to cancer cells.

Main Methods:

  • Synthesis and characterization of four thiosemicarbazone Ni-(II) complexes.
  • In vitro cytotoxicity assays on various cancer cell lines to determine IC50 values and selectivity.
  • Apoptosis induction studies, including DNA interaction and reactive oxygen species (ROS) balance analysis.
  • Cyclic voltammetry to characterize redox properties.
  • Albumin binding studies to assess delivery mechanisms.

Main Results:

  • The Ni4 complex exhibited significant cytotoxicity (IC50 down to 5 ± 2 μM) with over 8-fold selectivity.
  • Ni4 induces apoptosis via dual mechanisms: nuclear DNA minor groove coordination and disruption of ROS balance through interactions with radical species and catalytic hydrogen peroxide dismutation.
  • Ni4 treatment upregulated heme oxygenase (HO-1) and mitochondrial superoxide dismutase (SOD-2).
  • Albumin selectively binds and delivers Ni4 to cancer cells, with a high binding affinity (Kb: 1.5 ± 0.9 × 10^6 M^-1).

Conclusions:

  • Thiosemicarbazone Ni-(II) complexes, particularly Ni4, represent promising multimodal anticancer agents.
  • The selectivity of Ni4 is significantly enhanced by albumin-mediated delivery to cancer cells.
  • Understanding these mechanisms provides a foundation for developing targeted nickel-based cancer therapies.

Related Concept Videos

Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...